Table 3.
DNA ploidy assessment of 97 breast tumours analyzed.
| Characteristics | DNA ploidy status | ||
|---|---|---|---|
| Aneuploid with loss N (%) | Euploid N (%) | Aneuploid with gain* N (%) | |
| HER2 status based on HER2/CEP17 FISH: | |||
| Positive (N = 22) | 0 (0) | 5 (22.7) | 17 (77.3) |
| Negative (N = 75) | 1 (1.3)** | 33 (44.0) | 41 (54.7) |
| Partial loss of HER2 (N = 9) | 0 (0) | 4 (44.4) | 5 (55.6) |
| Number of chromosome 17 based on HER2/CEP17 FISH: | |||
| 1 | 1 (7.7) | 9 (69.2) | 3 (23.1) |
| 2 | 0 (0) | 25 (64.1) | 14 (35.9) |
| ≥3 | 0 (0) | 4 (8.9) | 41 (91.1) |
| p53 protein expression | |||
| Wildtype | 1 (1,5) | 32 (48,5) | 33 (50,0) |
| Mutant | 0 (0) | 6 (19,4) | 25 (80,6) |
| Overexpression | 0 (0) | 5 (21,7) | 18 (78,3) |
| Completely negative | 0 (0) | 1 (12,5) | 7 (87,5) |
N: number of cases. *Including tetraploidy. **Probably aneuploid with loss, although morphologically it was not possible to differentiate tumour nuclei from normal nuclei.